BioWorld

Jan. 12, 2005

View Archived Issues

Genentech Hits Consensus, But Avastin Sales Trouble Analysts

While Genentech Inc. logged a 43 percent jump in total product sales for 2004, analysts scrutinized the company's sales of Avastin, calling them modest and lethargic at best. (BioWorld Today) Read More

Dendreon's Stock Nosedives On Phase III Provenge Data

Read More

Sepracor Getting $20M Worth Of Acadia Shares In CNS Deal

Read More

New Exelixis, GSK Deal: Earlier Milestone Payments To Exelixis

Read More

Other News To Note

Read More

Appointments And Advancements

Read More